hydroxychloroquine has been researched along with Kidney Neoplasms in 4 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Kidney Neoplasms: Tumors or cancers of the KIDNEY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine is a tolerable autophagy inhibitor in future RCC or other trials." | 2.90 | Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma. ( Amaravadi, RK; Appleman, LJ; Davis, LE; Gimotty, PA; Haas, NB; Kadri, S; Kalavacharla, A; Kim, T; Onorati, A; Redlinger, M; Segal, JP; Stein, M; Wilks, M; Xu, X; Zhen, CJ, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, TM | 1 |
| Espitia, C | 1 |
| Wang, W | 1 |
| Nawrocki, ST | 1 |
| Carew, JS | 1 |
| Chhabra, R | 1 |
| Nanjundan, M | 1 |
| Haas, NB | 1 |
| Appleman, LJ | 1 |
| Stein, M | 1 |
| Redlinger, M | 1 |
| Wilks, M | 1 |
| Xu, X | 1 |
| Onorati, A | 1 |
| Kalavacharla, A | 1 |
| Kim, T | 1 |
| Zhen, CJ | 1 |
| Kadri, S | 1 |
| Segal, JP | 1 |
| Gimotty, PA | 1 |
| Davis, LE | 1 |
| Amaravadi, RK | 1 |
| Kobak, S | 1 |
| Karaarslan, A | 1 |
| Aktakka, Y | 1 |
1 trial available for hydroxychloroquine and Kidney Neoplasms
| Article | Year |
|---|---|
Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma | 2019 |
3 other studies available for hydroxychloroquine and Kidney Neoplasms
| Article | Year |
|---|---|
Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies.
Topics: Animals; Antineoplastic Agents; Autophagy; Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Hyd | 2019 |
Lysophosphatidic acid reverses Temsirolimus-induced changes in lipid droplets and mitochondrial networks in renal cancer cells.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Drug Resis | 2020 |
Renal cell carcinoma in a patient with rheumatoid arthritis treated with adalimumab.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthr | 2014 |